These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30216549)

  • 1. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ; Block CL; Laughlin DS; Oyama MA
    J Vet Intern Med; 2018 Sep; 32(5):1509-1516. PubMed ID: 30216549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    J Vet Cardiol; 2012 Sep; 14(3):399-408. PubMed ID: 22858663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
    J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
    Atkinson KJ; Fine DM; Thombs LA; Gorelick JJ; Durham HE
    J Vet Intern Med; 2009; 23(6):1190-6. PubMed ID: 19780931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
    Eriksson AS; Häggström J; Pedersen HD; Hansson K; Järvinen AK; Haukka J; Kvart C
    J Vet Cardiol; 2014 Sep; 16(3):141-54. PubMed ID: 25130405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease.
    Ogawa M; Hori Y; Kanno N; Iwasa N; Toyofuku T; Isayama N; Yoshikawa A; Akabane R; Sakatani A; Miyakawa H; Hsu HH; Miyagawa Y; Takemura N
    J Vet Med Sci; 2021 Apr; 83(4):705-715. PubMed ID: 33551383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations in dogs with mitral valve insufficiency.
    Takemura N; Toda N; Miyagawa Y; Asano K; Tejima K; Kanno N; Arisawa K; Kurita T; Nunokawa K; Hirakawa A; Tanaka S; Hirose H
    J Vet Med Sci; 2009 Jul; 71(7):925-9. PubMed ID: 19652480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
    Moesgaard SG; Falk T; Teerlink T; Guðmundsdóttir HH; Sigurðardóttir S; Rasmussen CE; Olsen LH
    Vet J; 2011 Sep; 189(3):349-52. PubMed ID: 20822939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of plasma N-terminal pro-brain natriuretic peptide concentrations to heart failure classification and cause of respiratory distress in dogs using a 2nd generation ELISA assay.
    Fox PR; Oyama MA; Hezzell MJ; Rush JE; Nguyenba TP; DeFrancesco TC; Lehmkuhl LB; Kellihan HB; Bulmer B; Gordon SG; Cunningham SM; MacGregor J; Stepien RL; Lefbom B; Adin D; Lamb K
    J Vet Intern Med; 2015 Jan; 29(1):171-9. PubMed ID: 25308881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?
    Chanmongkolpanit K; Riengvirodkij N; Channgam P; Kaenchan P; Buayam W; Janhirun Y; Phonarknguen R; Tansakul M; Sakcamduang W
    Open Vet J; 2024 Jun; 14(6):1426-1441. PubMed ID: 39055758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
    Mangkhang K; Punyapornwithaya V; Tankaew P; Pongkan W; Chattipakorn N; Boonyapakorn C
    Pol J Vet Sci; 2018 Dec; 21(4):673-680. PubMed ID: 30605282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
    Smith PJ; French AT; Van Israël N; Smith SG; Swift ST; Lee AJ; Corcoran BM; Dukes-McEwan J
    J Small Anim Pract; 2005 Mar; 46(3):121-30. PubMed ID: 15789807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Boswood A; Gordon SG; Häggström J; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
    J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
    Lake-Bakaar GA; Singh MK; Kass PH; Griffiths LG
    J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma atrial natriuretic peptide and N-terminal pro B-type natriuretic peptide concentrations in dogs with right-sided congestive heart failure.
    Kanno N; Hori Y; Hidaka Y; Chikazawa S; Kanai K; Hoshi F; Itoh N
    J Vet Med Sci; 2016 May; 78(4):535-42. PubMed ID: 26607133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease.
    Yata M; Kooistra HS; Beijerink NJ
    J Vet Intern Med; 2019 Mar; 33(2):462-470. PubMed ID: 30703246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.